WEBULL
WebtradeDownload

Everest Medicines Stock In Focus After China Approval For CARDAMYST

Simply Wall St · 3d ago
  • Everest Medicines has secured NMPA approval in China for CARDAMYST, a self-administered etripamil nasal spray for acute PSVT episodes, supported by multiple studies showing rapid rhythm conversion, at-home use, and generally mild side effects.
  • The launch of CARDAMYST as Everest Medicines' first cardiovascular therapy moves the business into a new treatment area with a large PSVT and AFib RVR patient pool across Greater China.
  • We will now look at how Everest Medicines' investment narrative could shift with NMPA approval for CARDAMYST and its at-home PSVT use.

Scan for other healthcare players that aim to shift treatment into patients' hands by running a quick filter on our curated list of 133 healthcare AI stocks aligned with tech-enabled care models.

Everest Medicines Investment Narrative Recap

To own Everest Medicines, you have to believe it can turn a broad portfolio in renal, autoimmune, infectious disease and now cardiovascular care into a repeatable commercial engine, not just a collection of licensed assets. CARDAMYST approval in China nudges the story away from heavy reliance on NEFECON, although the near term still looks defined by execution on existing launches.

Right now the key swing factor is whether recent product roll outs can move the group from ongoing losses to self-funding operations before further equity raises dilute you. CARDAMYST adds another potential revenue stream but also more commercial spend, so the main risk remains cash burn and pricing or reimbursement pushback across its core therapies.

The CARDAMYST data package is the standout recent update for this catalyst set. NMPA approval in September 2026, supported by conversion rates of 64% within 30 minutes in acute PSVT and long term NODE studies, gives Everest Medicines a differentiated, self administered cardiovascular therapy in a field where treatment has often been hospital based.

For investors watching catalysts, that shifts some attention from kidney and ulcerative colitis drugs toward execution in arrhythmia care. The burden of anxiety, lifestyle restriction and chronic symptoms shown in the longitudinal PSVT study also matters. It supports real world need, but commercial value still depends on pricing, reimbursement reach across Greater China and Everest’s ability to scale its cardiovascular sales infrastructure without letting costs run ahead of uptake.

Everest Medicines' current analyst narrative points to CN¥5.6b in revenue and CN¥878.3m in earnings by 2029. This is built on an assumed 48.8% yearly revenue growth rate and a swing in earnings of about CN¥1.18b from a loss of CN¥297.8m today to that 2029 consensus level.

Uncover why Everest Medicines' fair value indicates a 40% potential upside to its current price, which could narrow quickly.

SEHK:1952 1-Year Stock Price Chart
SEHK:1952 1-Year Stock Price Chart

Exploring Other Perspectives

One alternative view around Everest Medicines focuses less on CARDAMYST uptake and more on dilution risk. The most cautious analysts, working off pre-approval numbers, were still pencilling in CN¥5.2b of revenue and CN¥1.0b of earnings by 2029, yet only assigning a low-teen P/E. That gap shows how far opinions can diverge. Use this news as a prompt to compare several narratives before you commit capital.

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For More Investment Ideas Beyond Everest Medicines?

If the Everest Medicines story has sharpened your thinking about risk, reward and execution, you can use that same lens across a wider watchlist. The Simply Wall St Screener can help you focus on clear fundamentals rather than headlines.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.